New clinical study with Diamyd?s diabetes vaccine

Status
Not open for further replies.

Northerner

Admin (Retired)
Relationship to Diabetes
Type 1
Diamyd Medical AB reports that a new clinical study with the diabetes vaccine Diamyd? is planned to start in February 2013. In the study Diamyd? will be tested in a unique combination with other drugs, aiming to potentiate the effect of the diabetes vaccine. The Company has entered into an agreement with Link?ping University to conduct the researcher-initiated study. The study has been approved by the Swedish Medical Products Agency.
The study, which is the first study of its kind, combines the diabetes vaccine Diamyd? with relatively high doses of vitamin D and the anti-inflammatory drug ibuprofen. The purpose of the treatment is to preserve the body's own ability to control the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes.

?I am excited to start this new important study and I strongly believe in combining Diamyd? with vitamin D and anti-inflammatory drugs,? says Professor Johnny Ludvigsson at Link?ping University, principal investigator and sponsor of the study. ?The aim of the combination is to create favorable conditions for the diabetes vaccine Diamyd? to take effect by temporarily dampen the inflammation in the pancreas, while vitamin D is believed to strengthen the part of the immune system that Diamyd? should stimulate.?

http://www.diamyd.com/docs/pressClip.aspx?section=investor&ClipID=738266
 
Status
Not open for further replies.
Back
Top